Gregory Sivolapenko

1.8k total citations
57 papers, 1.4k citations indexed

About

Gregory Sivolapenko is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Gregory Sivolapenko has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Radiology, Nuclear Medicine and Imaging, 17 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Gregory Sivolapenko's work include Radiopharmaceutical Chemistry and Applications (20 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Colorectal Cancer Treatments and Studies (7 papers). Gregory Sivolapenko is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (20 papers), Monoclonal and Polyclonal Antibodies Research (19 papers) and Colorectal Cancer Treatments and Studies (7 papers). Gregory Sivolapenko collaborates with scholars based in Greece, United Kingdom and United States. Gregory Sivolapenko's co-authors include Haralabos P. Kalofonos, G. Hooker, A. A. Epenetos, D Snook, H Lambert, V Hird, Christopher McKenzie, Alastair J. Munro, B Dhokia and Agamemnon A. Epenetos and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Gregory Sivolapenko

56 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory Sivolapenko Greece 19 813 355 351 221 154 57 1.4k
Sagun Parakh Australia 19 395 0.5× 389 1.1× 892 2.5× 249 1.1× 306 2.0× 79 1.5k
R. E. Durand Canada 21 490 0.6× 753 2.1× 558 1.6× 42 0.2× 435 2.8× 38 2.6k
Chih‐Jung Chen Taiwan 26 123 0.2× 748 2.1× 527 1.5× 178 0.8× 264 1.7× 113 2.0k
Qin Xiao China 20 379 0.5× 819 2.3× 368 1.0× 114 0.5× 918 6.0× 92 1.9k
Nils Brünner Denmark 29 115 0.1× 1.2k 3.4× 1.0k 2.9× 226 1.0× 322 2.1× 96 2.4k
Martin Asslaber Austria 17 118 0.1× 508 1.4× 804 2.3× 589 2.7× 176 1.1× 35 1.8k
You Zhai China 17 142 0.2× 348 1.0× 243 0.7× 261 1.2× 166 1.1× 67 1.1k
Sérgio Rizzo Italy 25 81 0.1× 559 1.6× 1.0k 2.9× 230 1.0× 635 4.1× 74 2.0k
Odilia Popanda Germany 30 561 0.7× 1.7k 4.8× 577 1.6× 79 0.4× 340 2.2× 72 2.5k
Jochen Dahm‐Daphi Germany 26 262 0.3× 1.2k 3.5× 776 2.2× 56 0.3× 356 2.3× 45 1.7k

Countries citing papers authored by Gregory Sivolapenko

Since Specialization
Citations

This map shows the geographic impact of Gregory Sivolapenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Sivolapenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Sivolapenko more than expected).

Fields of papers citing papers by Gregory Sivolapenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Sivolapenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Sivolapenko. The network helps show where Gregory Sivolapenko may publish in the future.

Co-authorship network of co-authors of Gregory Sivolapenko

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Sivolapenko. A scholar is included among the top collaborators of Gregory Sivolapenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Sivolapenko. Gregory Sivolapenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liolis, Elias, Francesk Mulita, Αngelos Koutras, Thomas Makatsoris, & Gregory Sivolapenko. (2024). Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer. Materia Socio Medica. 36(4). 268–268. 2 indexed citations
2.
Karatza, Eleni, et al.. (2022). Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment. CPT Pharmacometrics & Systems Pharmacology. 11(10). 1328–1340. 4 indexed citations
3.
Chatziathanasiadou, Μaria V., George Α. Alexiou, Alexander Renziehausen, et al.. (2018). Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples. Journal of Pharmaceutical and Biomedical Analysis. 162. 164–170. 11 indexed citations
4.
Chatziathanasiadou, Μaria V., Efstathia Giannopoulou, Evangelos Briasoulis, et al.. (2018). Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 164. 690–697. 10 indexed citations
5.
Farsalinos, Konstantinos, et al.. (2018). Development and validation of analytical methodology for the quantification of aldehydes in e-cigarette aerosols using UHPLC-UV. Food and Chemical Toxicology. 116(Pt B). 147–151. 18 indexed citations
6.
Sivolapenko, Gregory, et al.. (2018). Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice. Analytical Biochemistry. 564-565. 72–79. 2 indexed citations
7.
Pippa, Νatassa, et al.. (2015). Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. Drug Delivery. 23(5). 1662–1666. 17 indexed citations
8.
Samantas, Epaminontas, Gerasimos Aravantinos, Haralabos P. Kalofonos, et al.. (2015). A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology. 75(4). 791–803. 42 indexed citations
9.
Pippa, Νatassa, et al.. (2014). Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives. Journal of Liposome Research. 25(2). 166–173. 6 indexed citations
10.
Travaini, Laura Lavinia, Silvia M. Baio, Marta Cremonesi, et al.. (2007). Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. The Breast. 16(3). 262–270. 9 indexed citations
11.
Cochand‐Priollet, Béatrix, et al.. (2006). Discriminating benign from malignant thyroid lesions using artificial intelligence and statistical selection of morphometric features. Oncology Reports. 15 Spec no.. 1023–6. 36 indexed citations
12.
13.
Sivolapenko, Gregory, et al.. (1998). Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. European Journal of Nuclear Medicine and Molecular Imaging. 25(10). 1383–1389. 80 indexed citations
14.
Sivolapenko, Gregory, et al.. (1996). Enhanced In Vivo Immunogenicity Induced by an Antibody to the IL‐4 Receptor‐Associated gp200‐MR6 Molecule. Scandinavian Journal of Immunology. 44(2). 135–142. 5 indexed citations
15.
Varvarigou, Alexandra D., et al.. (1996). Radiochemical and radioimmunological data of 99Tcm-anti-CEA labelled by two diverse methods. Nuclear Medicine Communications. 17(1). 80–88. 8 indexed citations
16.
Sivolapenko, Gregory, Κωνσταντίνος Κωνσταντινίδης, Dimitrios Pectasides, et al.. (1995). Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. The Lancet. 346(8991-8992). 1662–1666. 38 indexed citations
17.
Stewart, J.S.W., V Hird, D Snook, et al.. (1989). Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. International Journal of Radiation Oncology*Biology*Physics. 16(2). 405–413. 88 indexed citations
18.
Sivolapenko, Gregory, et al.. (1989). Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies. British Journal of Cancer. 60(4). 511–516. 2 indexed citations
19.
20.
Epenetos, A. A., Alastair J. Munro, Simon Stewart, et al.. (1987). Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.. Journal of Clinical Oncology. 5(12). 1890–1899. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sagun Parakh Breakdown of academic impact, for papers by R. E. Durand Breakdown of academic impact, for papers by Chih‐Jung Chen Breakdown of academic impact, for papers by Qin Xiao Breakdown of academic impact, for papers by Nils Brünner Breakdown of academic impact, for papers by Martin Asslaber Breakdown of academic impact, for papers by You Zhai Breakdown of academic impact, for papers by Sérgio Rizzo Breakdown of academic impact, for papers by Odilia Popanda Breakdown of academic impact, for papers by Jochen Dahm‐Daphi
Rankless by CCL
2026